Clinical Trial Update: Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial evaluating trastuzumab, with or without pertuzumab, in patients with gastric or gastroesophageal junction adenocarcinoma; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Pertuzumab (Perjeta) (pertuzumab)
• Trastuzumab (Herceptin) (trastuzumab)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Malignant Neoplasm of Stomach, Malignant Neoplasm of Cardio-esophageal Junction of Stomach | Phase 2 | Status: COMPLETED